Shockwave Medical, now a part of Johnson & Johnson MedTech, has consistently been found safe for patients. However, many previous clinical trials excluded high-risk patients, making it important to track real-world outcomes as time goes on.

President Donald Trump has crystallized his No. 1 priority for artificial intelligence. Unshockingly, it’s “winning the AI race.” 

AI can improve the quality of remotely delivered care while simultaneously defending privacy and security for the telehealth patient. 

In fact, more than 55% of all PCI cases in 2022 were performed using radial access. Cardiologists are sure to be keeping a close eye on this trend as time goes on.

Targeting high-risk patients with single-pill combination therapies, also known as polypills, could change healthcare on a global scale, according new data published in the Journal of the American College of Cardiology. 

Gen Xers and their elders tend to believe AI will do more harm than good. More than half of American adults 50 and older place themselves in that somewhat cynical category. 

When older patients undergo SAVR with concomitant procedures, it increases their short- and long-term risks of mortality. Should this influence care teams to consider more transcatheter treatments? 

AI can hurt or help the cause of advancing equality of resources, services and outcomes in healthcare. If it’s to do more helping than hurting, the technology must permeate primary care—and do so with certain goals and guidelines.